Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3057% above fair value
$105.80−0.01 (-0.01%)
Close on Nov 12, 2026Market cap $60.98BP/E 59.8Yield –
Edwards Lifesciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Edwards Lifesciences's ebitda for the twelve months ending Sep 30, 2026 was $1.61B, up 1.9% year over year. For fiscal 2025 it was $1.42B, down 7.4% from the year before. The highest annual figure on record is $1.83B in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.42B | -7.4% |
| FY2024 | Dec 31, 2024 | $1.53B | +5.5% |
| FY2023 | Dec 31, 2023 | $1.45B | -11.2% |
| FY2022 | Dec 31, 2022 | $1.64B | -10.3% |
| FY2021 | Dec 31, 2021 | $1.83B | +81.6% |
| FY2020 | Dec 31, 2020 | $1.00B | -18.7% |
| FY2019 | Dec 31, 2019 | $1.24B | +49.7% |
| FY2018 | Dec 31, 2018 | $825.60M | -29.5% |
| FY2017 | Dec 31, 2017 | $1.17B | +42.4% |
| FY2016 | Dec 31, 2016 | $822.40M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $344.00M | -0.7% |
| Q2 FY2026 | Jun 30, 2026 | $555.90M | +23.7% |
| Q1 FY2026 | Mar 31, 2026 | $518.50M | +20.2% |
| Q4 FY2025 | Dec 31, 2025 | $193.80M | -45.4% |
| Q3 FY2025 | Sep 30, 2025 | $346.30M | -10.1% |
| Q2 FY2025 | Jun 30, 2025 | $449.30M | +10.6% |
| Q1 FY2025 | Mar 31, 2025 | $431.40M | +11.3% |
| Q4 FY2024 | Dec 31, 2024 | $355.20M | -7.4% |
| Q3 FY2024 | Sep 30, 2024 | $385.10M | -4.4% |
| Q2 FY2024 | Jun 30, 2024 | $406.10M | +35.5% |
| Q1 FY2024 | Mar 31, 2024 | $387.50M | -8.5% |
| Q4 FY2023 | Dec 31, 2023 | $383.50M | +64.5% |
| Q3 FY2023 | Sep 30, 2023 | $402.80M | -8.0% |
| Q2 FY2023 | Jun 30, 2023 | $299.60M | -39.3% |
| Q1 FY2023 | Mar 31, 2023 | $423.60M | -10.5% |
| Q4 FY2022 | Dec 31, 2022 | $233.10M | -42.8% |
| Q3 FY2022 | Sep 30, 2022 | $437.80M | +3.3% |
| Q2 FY2022 | Jun 30, 2022 | $493.60M | -14.6% |
| Q1 FY2022 | Mar 31, 2022 | $473.50M | +13.8% |
| Q4 FY2021 | Dec 31, 2021 | $407.40M | +6.1% |
| Q3 FY2021 | Sep 30, 2021 | $423.90M | +10.6% |
| Q2 FY2021 | Jun 30, 2021 | $577.90M | – |
| Q1 FY2021 | Mar 31, 2021 | $415.90M | +8.7% |
| Q4 FY2020 | Dec 31, 2020 | $384.00M | +14.7% |
| Q3 FY2020 | Sep 30, 2020 | $383.40M | +20.8% |
| Q2 FY2020 | Jun 30, 2020 | -$145.20M | -150.2% |
| Q1 FY2020 | Mar 31, 2020 | $382.60M | +29.8% |
| Q4 FY2019 | Dec 31, 2019 | $334.70M | +2192.5% |
| Q3 FY2019 | Sep 30, 2019 | $317.40M | +18.4% |
| Q2 FY2019 | Jun 30, 2019 | $289.20M | +6.6% |
| Q1 FY2019 | Mar 31, 2019 | $294.80M | +8.5% |
| Q4 FY2018 | Dec 31, 2018 | $14.60M | -95.9% |
| Q3 FY2018 | Sep 30, 2018 | $268.10M | +14.2% |
| Q2 FY2018 | Jun 30, 2018 | $271.30M | +4.4% |
| Q1 FY2018 | Mar 31, 2018 | $271.60M | -15.0% |
| Q4 FY2017 | Dec 31, 2017 | $357.30M | – |
| Q3 FY2017 | Sep 30, 2017 | $234.70M | – |
| Q2 FY2017 | Jun 30, 2017 | $259.90M | – |
| Q1 FY2017 | Mar 31, 2017 | $319.40M | – |
See a number that looks wrong?